8-K: IN8bio Reports Q2 2026 Results, Advances T Cell Therapies

IN8bio announced second quarter 2026 financial results, showcasing advancements in its gamma delta T cell engager platform and positive clinical data for its glioblastoma treatment.

Summary

• IN8bio reported its financial results for the second quarter ended June 30, 2026.
• The company is advancing its next-generation gamma delta T cell engager (TCE) platform, with initial in vivo data for INB-619 expected in the second half of 2026.
• Updated clinical data for DeltEx Drug Resistant Immunotherapy (DRI) in newly diagnosed glioblastoma (GBM) showed a median overall survival (mOS) exceeding 19.5 months.
• Peer-reviewed data published in The Journal of Clinical Oncology demonstrated DeltEx DRI more than doubled expected median progression-free survival (mPFS) in newly diagnosed GBM patients.
• New translational AI proteomic and immunogenomic analyses suggest DeltEx DRI preserves immune function and positively remodels the GBM tumor microenvironment.
• The company had $18.0 million in cash as of June 30, 2026.
• Net loss for the quarter was $4.8 million, or $0.25 per share, an improvement from the prior year's net loss of $5.1 million, or $1.24 per share.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, highlighting significant clinical progress and data validation, though financial losses persist and capital needs remain a consideration.

Positives

• Updated clinical data for DeltEx DRI in newly diagnosed GBM showed median overall survival (mOS) exceeding 19.5 months, compared to 13.2 months for standard-of-care.
• Median progression-free survival (mPFS) for repeat-dose DeltEx DRI patients was 13.0 months versus 6.6 months for contemporaneously enrolled patients receiving only standard-of-care.
• Approximately 43% of repeat-dose patients remained alive at 24 months, compared to 20% of standard-of-care patients.
• No dose-limiting toxicities (DLTs), cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome (ICANS) were observed in the Phase 1 INB-200 trial.
• New translational data indicates DeltEx DRI preserves immune function and positively remodels the GBM tumor microenvironment, with an 18-fold increase in intratumoral CD8+ T cell density.
• Cash position increased to $18.0 million from $13.2 million in the prior year period.
• Net loss per share improved to $0.25 from $1.24 in the prior year period.

Negatives

• The company reported a net loss of $4.8 million for the three months ended June 30, 2026.
• The company had $18.0 million in cash as of June 30, 2026, which may require future capital raises to fund ongoing operations and development.
• Research and Development expenses were $2.5 million for the quarter, indicating continued investment in pipeline development.

Risks

• The company may be unable to raise additional capital and could be forced to delay, further reduce, or explore other strategic options for certain development programs, or even terminate its operations.
• Uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of product candidates.
• The risk that trials and studies may be delayed and may not have satisfactory outcomes.
• Potential adverse effects arising from the testing or use of product candidates.
• The uncertainty of regulatory approvals to conduct trials or to market products.
• Reliance on third parties, including licensors and clinical research organizations.

Future Outlook

Initial in vivo preclinical data for INB-619 is expected in the second half of 2026. The company is seeking FDA discussions regarding potential regulatory pathways for the DeltEx DRI GBM program. An INB-100 program clinical update is anticipated in late 2026, with additional clinical and translational updates from the DeltEx DRI GBM program to follow.

Management Comments

• "Our gamma delta T cell engager platform is progressing, with INB-619 advancing into initial animal models. We are pleased to remain on track for reporting initial in vivo data this year."
• "In addition, peer-reviewed and updated clinical data from our glioblastoma program continue to demonstrate a favorable safety profile and provide strong evidence that T cells are clinically active and can be delivered safely to potentially improve patient outcomes."
• "We remain focused on disciplined execution, as we continue to seek a regulatory pathway for our glioblastoma program, with the ultimate goal of bringing much needed treatment to patients."

Industry Context

StockSavvy.ai notes that IN8bio's progress aligns with the broader industry trend of advancing novel cell therapies, particularly gamma delta T cells, which are gaining traction due to their potential for improved safety and efficacy profiles compared to traditional CAR-T therapies. The focus on glioblastoma, a notoriously difficult-to-treat cancer, also reflects the industry's pursuit of treatments for high unmet medical needs.

Comparison to Industry Standards

• The median overall survival (mOS) of over 19.5 months for DeltEx DRI treated patients in newly diagnosed GBM significantly exceeds the typical mOS for standard-of-care treatments, which is generally around 13-15 months.
• The doubling of median progression-free survival (mPFS) compared to standard-of-care (13.0 months vs. 6.6 months) is a substantial improvement, though direct comparisons are limited by the specific patient population and treatment regimen.
• The observed increase in intratumoral CD8+ T cell density (18-fold) and reduction in immunosuppressive granulocytes are promising mechanistic insights that align with successful immunotherapy strategies seen in other solid tumors, though GBM remains a challenging indication.

Stakeholder Impact

• Shareholders: The positive clinical data may lead to increased investor confidence, while the ongoing net losses and potential need for capital raises present risks.
• Patients: Advancements in DeltEx DRI offer potential new treatment options for GBM patients with improved survival outcomes.
• Employees: Continued R&D investment and progress in clinical trials support the company's mission and potential growth.

Next Steps

• Report initial preclinical animal data for INB-619 in the second half of 2026.
• Report on FDA discussions regarding the potential regulatory pathways for the DeltEx DRI GBM program.
• Provide a clinical update for the INB-100 program at a scientific meeting in late 2026.
• Provide additional clinical and translational updates from the DeltEx DRI GBM program.

Key Dates

Recommendation

The company is showing promising clinical data and advancing its pipeline, which is positive. However, it continues to incur significant net losses and relies on future capital raises, creating financial risk. The current stage of development and financial situation warrants a 'hold' recommendation, pending further de-risking of the clinical and financial outlook.

Keywords

T cell therapy, Glioblastoma, Cancer immunotherapy, Clinical trial, Biopharmaceutical, Drug development, T cell engager, Oncology